It was a pleasure to speak with Louis Picker (VGTI-Vaccine and Gene Therapy Institute, Oregon Health & Science University, Portland, OR, USA) to discuss his work in CMV-vector vaccines for HIV prevention.
The abstract entitled: ‘CMV-vectored vaccines for HIV prevention’ (SY09.03) was presented at the HIVR4P Virtual Conference 2021, 04 February 2021.
Questions:
- Could you give us an overview of the current status of vaccine development for HIV and its unmet needs? (0:14)
- What is the rationale for using cytomegalovirus (CMV) as a vaccine vector for HIV? (0:29)
- What are the challenges in the development and use of CMV-vectored vaccines? (4:05)
- What preclinical and clinical evidence supports the use of CMV-vectored vaccines? (6:28)
- What safety concerns are associated with this approach? (8:25)
Disclosures: Louis Picker is the Founder of, and Consultant for, Vir Biotechnology, Inc., which is developing CMV-based vaccine vector for clinical use.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Katey Gabrysch.
Filmed as a highlight of HIVR4P Virtual 2021.
